Nova is built for a new era of clinical development
Regulatory agencies are raising expectations for dose optimization across oncology and beyond, and the traditional maximum tolerated dose paradigm is no longer sufficient. Learn why the industry is changing, and how precision dosing addresses it.
Nova can support trials across oncology, gene therapy, transplant, and rare disease programs, enabling precision dosing from Phase I through post-approval studies. Whether your trial involves high-variability conditioning agents, narrow therapeutic index drugs, or pediatric populations with limited PK data, Nova's Bayesian platform adapts to the demands of your specific protocol.
Feature: Companion Apps
Bring new therapies to market with drug-specific dosing companions.
Companion apps are drug-specific dosing tools built on the InsightRX platform and branded for your therapy. They put validated, model-informed dose guidance directly into the workflows of providers using your drug.
Delivers validated, drug-specific dose guidance to prescribers in the workflows they already use- Supports post-approval and Phase IV commitments with real-world dosing data collected across deployment
- Equips MSLs with tools to drive data-backed conversations on therapy management and outcomes
